BioNTech and Bristol Myers Squibb Partner for Global Development of BNT327

The latest announcement is out from BioNTech SE ( (BNTX) ).

On June 2, 2025, BioNTech SE and Bristol Myers Squibb announced a strategic partnership to co-develop and co-commercialize BioNTech’s investigational bispecific antibody BNT327 for multiple solid tumor types. This collaboration aims to leverage both companies’ expertise to accelerate BNT327’s development and potential market launch. BNT327, which targets PD-L1 and VEGF-A, is in advanced clinical trials and shows promise in improving treatment outcomes for various cancers. The agreement includes a 50/50 profit and loss split and involves significant financial commitments from Bristol Myers Squibb, including an upfront payment and potential milestone payments. This partnership is expected to enhance BioNTech’s position in the oncology market and provide transformative treatment options for patients.

The most recent analyst rating on (BNTX) stock is a Buy with a $171.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

Spark’s Take on BNTX Stock

According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.

BioNTech’s overall stock score reflects a mixed financial outlook with a strong balance sheet but issues in profitability and cash flow. The stock is technically weak with a negative MACD and RSI, suggesting a bearish momentum. Valuation concerns arise from a negative P/E ratio, and while the company is making strategic advancements, financial challenges from reduced revenues and high costs weigh on the score.

To see Spark’s full report on BNTX stock, click here.

More about BioNTech SE

BioNTech SE is a global next-generation immunotherapy company focused on developing novel investigative therapies for cancer and other serious diseases. The company leverages a wide array of computational discovery and therapeutic modalities to rapidly develop novel biopharmaceuticals, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates and CAR T cell therapies. BioNTech collaborates with multiple global and specialized pharmaceutical companies.

Average Trading Volume: 1,112,829

Technical Sentiment Signal: Sell

Current Market Cap: $23.03B

Find detailed analytics on BNTX stock on TipRanks’ Stock Analysis page.